AJMC - Change is Coming
|Articles|June 21, 2021

Evidence-Based Oncology

  • June 2021
  • Volume 27
  • Issue 4

Weidner et al, Appendices

Appendices to: Observations Regarding the Average Sales Price Reimbursement Methodology

eAPPENDICES Weidner et al

Articles in this issue

over 4 years ago

Dollars and Sense

over 4 years ago

FDA Panel Votes to Keep 4 of 6 “Dangling Approvals,” in a Sign of Things to Come

over 4 years ago

Observations Regarding the Average Sales Price Reimbursement Methodology

over 4 years ago

Real-World Evidence Is Key to Accelerating Oncology Approvals

over 4 years ago

PATHWAYS: Oncology Care Pathways Launched by Payers: What Are the Trends?

over 4 years ago

Biosimilars Drive Savings in Medicare’s Oncology Care Model

over 4 years ago

A Social Worker Leads ACCC, and Her Timing Is Perfect

over 4 years ago

After PD-1 Inhibitor Indications Are Withdrawn in SCLC, What Now?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs
Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

View more
Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text